Sail Biomedicines, a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Martin ...

German Merck KGaA’s recently acquired subsidiary SpringWorks Therapeutics today announced that long-term efficacy and safety data from the Phase III DeFi trial of Ogsiveo (nirogacestat) were in the ...

Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in ...

SpringWorks Therapeutics Inc. shares SWTX were on track for a record percentage gain on Tuesday after the company got the first U.S. regulatory approval for a drug targeting a rare type of ...

The biggest M&A activity of the year arrived in the form of Merck KGaA’s earlier-disclosed agreement to buy Springworks Therapeutics Inc. for $47 per share in cash, which represents an equity value of ...

STAMFORD, Conn., April 27, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced ...

Shares of SpringWorks Therapeutics climbed after The Wall Street Journal reported that Germany's Merck KGaA is nearing a $3.5 billion deal for the U.S. biopharmaceutical company. SpringWorks stock ...

(Reuters) - Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 billion, a deal that could give it access to a recently ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) stands against other best ...